Mycophenolate Mofetil Hydrochloride
Mycophenolate mofetil hydrochloride is the hydrochloride salt form of mycophenolate mofetil, a semi-synthetic immunosuppressant derived from mycophenolic acid with a morpholinoethyl ester group. It falls under HTS 2934.99.01.00 as a specific aromatic heterocyclic compound used primarily to prevent organ transplant rejection by inhibiting lymphocyte proliferation. This chemically defined compound contains a fused heterocyclic ring system characteristic of Chapter 29 heading 2934.
Import Duty Rates by Country of Origin
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If classified as a natural antibiotic derivative
Mycophenolic acid derivatives could be considered under antibiotics if primary function emphasized over immunosuppressant use.
If for bulk vegetable alkaloids without specific ester modification
Parent mycophenolic acid might classify under vegetable alkaloids if not meeting exact mycophenolate mofetil specification.
If imported as formulated capsules rather than bulk powder
Finished medicaments in dosage form move to Chapter 30, not remaining in Chapter 29 for bulk chemicals.
Not sure which classification is right?
Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.
Import Tips & Compliance
• Obtain FDA approval and Drug Master File (DMF) documentation prior to importation as this is a bulk pharmaceutical chemical
• Ensure Certificate of Analysis (CoA) verifies purity >98% and confirms identity via HPLC matching reference standards
• Avoid misclassification as a finished dosage form; provide documentation proving it's bulk API not formulated tablets/capsules
Related Products under HTS 2934.99.01.00
Mycophenolate Mofetil Free Base Powder
Pure mycophenolate mofetil free base in pharmaceutical-grade powder form serves as the active pharmaceutical ingredient (API) for generic immunosuppressant production. Classified under HTS 2934.99.01.00 as the specific aromatic heterocyclic compound, it features the characteristic morpholinoester structure on the mycophenolic acid backbone. Used exclusively in manufacturing formulations for preventing organ rejection.
Pharmaceutical Grade Mycophenolate Mofetil USP
Mycophenolate mofetil meeting United States Pharmacopeia (USP) standards for use in FDA-approved generic drug manufacturing. This specific aromatic heterocyclic immunosuppressant falls under HTS 2934.99.01.00 per Chapter 29 notes for chemically defined organic compounds. The product's fused ring system with ester functionality defines its precise tariff classification.
Mycophenolate Mofetil EP Reference Standard
European Pharmacopoeia reference standard of mycophenolate mofetil used for analytical method validation and quality control testing. As a chemically defined aromatic heterocyclic compound, it precisely matches HTS 2934.99.01.00 specifications. Supplied in certified amounts (typically 100mg vials) for HPLC/GC calibration.
Bulk Mycophenolate Mofetil API for Generic Production
Large-quantity bulk API mycophenolate mofetil specifically manufactured for generic pharmaceutical production of transplant rejection medications. Falls under HTS 2934.99.01.00 as the named aromatic heterocyclic compound per Chapter 29 legal notes. Chemically defined with specific morpholinoethyl ester structure distinguishing from other mycophenolic derivatives.
Mycophenolate Mofetil Morpholino Ester
The specific morpholinoethyl ester prodrug form of mycophenolic acid, chemically defined as mycophenolate mofetil under HTS 2934.99.01.00. This aromatic heterocyclic compound converts in vivo to active mycophenolic acid via esterase cleavage. Essential API for branded CellCept® and generic equivalents.
Sterile Mycophenolate Mofetil for Injection Formulation
Sterile-grade mycophenolate mofetil powder intended for IV injection formulation after further processing. Classified under HTS 2934.99.01.00 as bulk aromatic heterocyclic API despite sterile processing, per Chapter 29 notes excluding only finished medicaments. Meets parenteral quality standards with endotoxin limits <0.5 EU/mg.